Orphan drug designation: Intellectual property safety net

被引：0

|

作者：

Emont, G ^{[1
]}

机构：

[1] ONCOTHERAPEUT INC,BUSINESS DEV,CRANBURY,NJ 08512

来源：

BIOPHARM-THE TECHNOLOGY & BUSINESS OF BIOPHARMACEUTICALS | 1995年 / 8卷 / 03期

关键词：

D O I：

暂无

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

引用

收藏

页码：17 / &

页数：5

相关论文

共 50 条

[31] The routes to orphan drug designation - our recent experience at the FDA
Lev, Daniel
Thorat, Chandana
Phillips, Ian
Thomas, Mathew
Imoisili, Menfo A.
DRUG DISCOVERY TODAY, 2012, 17 (3-4) : 97 - 99
[32] Two more biotechnology products receive orphan drug designation
不详
BIOTECHNOLOGY LAW REPORT, 2000, 19 (04) : 417 - 417
[33] Hemophilia drug OBI-1 receives orphan drug designation in Europe
Reeve, Emily
EXPERT REVIEW OF HEMATOLOGY, 2010, 3 (06) : 662 - 662
[34] A politics of intellectual property: Environmentalism for the net?
Boyle, J
DUKE LAW JOURNAL, 1997, 47 (01) : 87 - 116
[35] NEGOTIATION OUTCOMES IN ITALY: WHAT'S THE IMPACT OF ORPHAN DRUG DESIGNATION?
Enrici, A.
Lidonnici, D.
Lanati, E.
VALUE IN HEALTH, 2019, 22 : S716 - S717
[36] HGS receives orphan drug designation for antibody-stimulating protein
不详
BIOTECHNOLOGY LAW REPORT, 2001, 20 (04) : 554 - 554
[37] Orphan drug designation and development in Japan: 25 years of experience and assessment
Sakushima, Ken
Takeda, Hiroshi
Aoi, Yoko
NATURE REVIEWS DRUG DISCOVERY, 2021, 20 (12) : 893 - 894
[38] Orphan drug designation and development in Japan: 25 years of experience and assessment
Ken Sakushima
Hiroshi Takeda
Yoko Aoi
Nature Reviews Drug Discovery, 2021, 20 : 893 - 894
[39] FDA Grants Orphan Drug Designation for 68Ga-DOTATOC
不详
JOURNAL OF NUCLEAR MEDICINE, 2014, 55 (01)
[40] ORPHAN BUSINESS MODELS: TOWARD A NEW FORM OF INTELLECTUAL PROPERTY
Abramowicz, Michael
HARVARD LAW REVIEW, 2011, 124 (06) : 1362 - 1421

← 1 2 3 4 5 →